Presentation is loading. Please wait.

Presentation is loading. Please wait.

GBM width (A), Vv(Mes/glom) (B), Vv(MM/glom) (C), Vv(MC/glom) (D), and Vv(MM/mes) (E) in one-kidney patients with (open diamond) and without (closed diamond)

Published byWidyawati Irawan Modified over 5 years ago

Similar presentations

Presentation on theme: "GBM width (A), Vv(Mes/glom) (B), Vv(MM/glom) (C), Vv(MC/glom) (D), and Vv(MM/mes) (E) in one-kidney patients with (open diamond) and without (closed diamond)"— Presentation transcript:

1 GBM width (A), Vv(Mes/glom) (B), Vv(MM/glom) (C), Vv(MC/glom) (D), and Vv(MM/mes) (E) in one-kidney patients with (open diamond) and without (closed diamond) ACE inhibitor therapy and two-kidney patients with (open triangle) and without (closed triangle) ACE inhibitor therapy. GBM width (A), Vv(Mes/glom) (B), Vv(MM/glom) (C), Vv(MC/glom) (D), and Vv(MM/mes) (E) in one-kidney patients with (open diamond) and without (closed diamond) ACE inhibitor therapy and two-kidney patients with (open triangle) and without (closed triangle) ACE inhibitor therapy. The shaded area is 5 and 95% CI for the control subjects (A) and mean ± 2 SD for the control subjects (B–E). Shirley Chang et al. Diabetes 2008;57: ©2008 by American Diabetes Association

Download ppt "GBM width (A), Vv(Mes/glom) (B), Vv(MM/glom) (C), Vv(MC/glom) (D), and Vv(MM/mes) (E) in one-kidney patients with (open diamond) and without (closed diamond)"

Similar presentations

Dose-escalation patient response.

Dose-escalation patient response.
WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,

WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,
Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.
Volume 70, Issue 8, Pages (October 2006)

Volume 70, Issue 8, Pages (October 2006)
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Current Therapy for Type II Diabetes

Current Therapy for Type II Diabetes
A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.
Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors

Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors
Figure 5 Risk factor control in the intensive treatment group

Figure 5 Risk factor control in the intensive treatment group
Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.
Depicted are patient and disease factors used to determine optimal A1C targets. Depicted are patient and disease factors used to determine optimal A1C.

Depicted are patient and disease factors used to determine optimal A1C targets. Depicted are patient and disease factors used to determine optimal A1C.
Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.

Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.
Outcomes with dual RAAS inhibition with an ACE inhibitor and ARB vs standard therapy in patients on hemodialysis with CHF standard therapy in patients.

Outcomes with dual RAAS inhibition with an ACE inhibitor and ARB vs standard therapy in patients on hemodialysis with CHF standard therapy in patients.
Prevalence of depression severity according to the stage of diabetic nephropathy. Prevalence of depression severity according to the stage of diabetic.

Prevalence of depression severity according to the stage of diabetic nephropathy. Prevalence of depression severity according to the stage of diabetic.
Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.
Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.
(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.

(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.
Prevalence of microvascular and macrovascular complications compared between cohort 1 and cohort 2 for subjects with type 2 (A, upper panel) and type 1.

Prevalence of microvascular and macrovascular complications compared between cohort 1 and cohort 2 for subjects with type 2 (A, upper panel) and type 1.
Inclusion process. Inclusion process. Of 5200 eligible patients, 204 declined participation, 111 had diabetes >400 days before All New Diabetics in Scania.

Inclusion process. Inclusion process. Of 5200 eligible patients, 204 declined participation, 111 had diabetes >400 days before All New Diabetics in Scania.
Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.

Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.

Similar presentations

Ads by Google